Precision medicine to improve the risk and benefit of cancer care: Genetic factors in vincristine-related neuropathy
Menée sur 321 patients pédiatriques atteints d'une leucémie lymphoblastique aiguë, cette étude met en évidence une association entre un polymorphisme constitutionnel dans la région promotrice du gène CEP72 et la survenue d'une neuropathie périphérique liée à un traitement à base de vincristine
The past decade has seen important advances in the treatment of many cancers, with curative therapies for a few and extension of quantity and quality of life for others.1- 3 For example, clarifying the role of both growth factor cell signaling and immunologic checkpoints in advanced melanoma has produced kinase inhibitors and immunotherapy drugs that each produce longer patient survival than any previous treatments. These improvements reflect efforts in pharmacology and cancer biology and the success of translating the biochemical, pharmacological, immunological, and molecular findings into treatments. This has allowed the practical emergence of personalized medicine for cancer management, whereby genetic variants, gene expression, and other patient factors allow for more objective selection of therapeutic regimens, individualized dosing of drugs, and the possibility of avoiding drug toxicity.
JAMA , éditorial, 2014